Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peripheral parenteral nutrition for moderately preterm infants
ACTRN12616000925448Phase 3Recruiting
- Sponsor
- Women's and Children's Health Network
- Start
- Sep 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of l-leucine, SMOFlipid, glucose and heparin in extrauterine growth restriction (EUGR) and preterm birth (2 arms), sponsored by Women's and Children's Health Network. Primary endpoint: Rate of weight gain from birth to 21 days. Started Sep 2016; status: recruiting.
02
Drugs
l-leucineSMOFlipidglucoseheparin
03
Conditions
extrauterine growth restriction (EUGR)preterm birth
Beyond the preview
Go deeper on ACTRN12616000925448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000925448.